Ole Schmitz

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007 · 467 citations · Full text

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Kristine B. Degn, Claus Bogh Juhl, Jeppe Sturis et al. · Diabetes · 2004 · 424 citations · Full text

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)

Sten Madsbad, Ole Schmitz, Jonas Ranstam et al. · Diabetes Care · 2004 · 309 citations · Full text

Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia

Kristine B. Degn, Birgitte Brock, Claus Bogh Juhl et al. · Diabetes · 2004 · 253 citations · Full text

Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome

Esben Selmer Buhl, Niels Jessen, Rasmus Pold et al. · Diabetes · 2002 · 240 citations · Full text

Rats Displaying Features, Hypertension, Insulin Resistance Syndrome +19